Dr. Farah is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5115 Centre Ave
Pittsburgh, PA 15232Phone+1 412-864-6600Fax+1 412-864-6669
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2008 - 2010
Zucker School of Medicine at Hofstra/Northwell at Staten Island University HospitalResidency, Internal Medicine, 2002 - 2005
St Joseph's University Medical SchoolClass of 1997
Certifications & Licensure
PA State Medical License 2012 - 2024
WA State Medical License 2005 - 2014- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Computer-Guided Glucose Management Systems in Treating Patients With Hyperglycemia Who Have Undergone Blood and Bone Marrow Transplant Start of enrollment: 2012 Dec 01
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Start of enrollment: 2015 Feb 11
Publications & Presentations
PubMed
- A phase II study of post-remission therapy with pembrolizumab in older patients with acute myeloid leukemia.Kevin Quann, Konstantinos Lontos, Alison Sehgal, Anastasios Raptis, Annie Im
Haematologica. 2024-12-01 - 1 citationsCombination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D Phelan, Da Wei Huang
The New England Journal of Medicine. 2024-06-20 - 1 citationsPhase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients.Annie Im, Kevin Quann, Mounzer Agha, Anastasios Raptis, Robert L Redner
American Journal of Hematology. 2024-03-01
Abstracts/Posters
- Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...Rafic Farah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...Rafic Farah, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
OncLive® Presents State of the Science Summit™June 3rd, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
